AICAR accumulation leads to decreased one-carbon metabolism gene expression, cell proliferation, and increased global bioenergetic capacity via AMPK activation (12)
With peptides, we can usually adjust the dosage to reduce this effect
One of the most promising pharmacological approaches for the management of type 2 diabetes takes advantage of the peptide hormone glucagon-like peptide-1 (GLP-1) under the form of protease resistant mimetics, and DPP-IV inhibitors
Under the brand name Wegovy , its FDA-approved for weight loss in people with overweight and obesity
You can find the protocol for this review here: Michael Nunns Ilianna Lourida, PhD Samantha Febrey Jo Thompson Coon Dr Pooja Sharma Oswal Elizabeth Shaw Tilly Vivia Wilson Alison Bethel Allison Stitt Rebecca Whear Becca Abbott Kate Boddy Kieran Becker Simon Russell To view or add a comment, sign in What if the biggest advancement in obesity care isn't a new medication
Using it now is risking putting yourself back at square one